Evaluation of dosing strategy for pembrolizumab for oncology indications

Table 1 Number of patients with observed PK concentration data used in the analysis by study, cancer type and dosing regimen

Study	Cancer Type	2 mg/kg Q3W	10 mg/kg Q3W	10 mg/kg Q2W	200 mg Q3W
KEYNOTE-001	Melanoma	165	309	176
KEYNOTE-001	NSCLC	61	288	204
KEYNOTE-002	Melanoma	207	212
KEYNOTE-006	Melanoma		270	272
KEYNOTE-010	NSCLC	327	326
KEYNOTE-024	NSCLC				152
KEYNOTE-045	Urothelial Cancer				262
KEYNOTE-052	Urothelial Cancer				311
KEYNOTE-055	HNSCC				47
KEYNOTE-164	MSI-H				58

There are patients with missing indication for N = 24 from KEYNOTE-001, 002 and 006
NSCLC Non–Small Cell Lung Cancer, HNSCC Head and Neck Squamous Cell Carcinoma, MSI-H Microsatellite Instability-High Carcinoma